Angion Biomedica (ANGN) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Justin Kim assigned a Buy rating to Angion Biomedica (ANGN) today and set a price target of $38.00. The company’s shares closed last Monday at $13.82, close to its 52-week low of $12.56.

According to, Kim is a 4-star analyst with an average return of 20.4% and a 49.2% success rate. Kim covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Apellis Pharmaceuticals, and Aldeyra Therapeutics.

Currently, the analyst consensus on Angion Biomedica is a Strong Buy with an average price target of $59.33.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Angion Biomedica Corp was incorporated in the State of Delaware on April 6. 1998. It is a clinical stage biopharmaceutical company. The Company discovers and develops novel therapeutic agents to treat acute and chronic organ injury by harnessing the body’s protective, reparative and regenerative systems. It is developing therapeutics for both orphan indications and large clinical markets of unmet medical need.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts